Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
Public ClinicalTrials.gov record NCT02592798. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change Disease)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD). Candidates must have a prior kidney biopsy with either diagnosis. Another kidney biopsy will not be required as part of the study. Candidates must have failed or be intolerant of prior therapy for their kidney disease. The failed or intolerant therapy must include corticosteroids and at least one other drug. Candidates can be adults and children over the age of 6. Abatacept will be administered by venous infusion every 4 weeks.
Study identification
- NCT ID
- NCT02592798
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 36 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 6 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 9, 2016 (Actual)
- Primary completion
- Jan 28, 2020 (Actual)
- Completion
- Jan 28, 2020 (Actual)
- Last update posted
- Mar 5, 2021
2016 – 2020
United States locations
- U.S. sites
- 27
- U.S. states
- 17
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University Of Alabama At Birmingham | Birmingham | Alabama | 35233 | — |
| University of Alabama-Birmingham-Parent Account | Birmingham | Alabama | 35294 | — |
| Los Angeles Biomedical Research Institute | Torrance | California | 90502 | — |
| University Of Colorado Denver | Aurora | Colorado | 80045 | — |
| Children's National Health System | Washington D.C. | District of Columbia | 20010 | — |
| University Of Miami Miller School Of Medicine | Miami | Florida | 33136 | — |
| Nemours Childrens Hospital | Orlando | Florida | 32827 | — |
| Emory University | Atlanta | Georgia | 30322-1015 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| NIH Clinical Center - NIDDK | Bethesda | Maryland | 20892 | — |
| Boston Childrens Hospital | Boston | Massachusetts | 02115 | — |
| Brigham And Women'S Hosp Inc. | Boston | Massachusetts | 02115 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Childrens Mercy Hospital | Kansas City | Missouri | 64108 | — |
| New York University Langone Medical Center | New York | New York | 10016 | — |
| Columbia University Medical Center (Cumc) | New York | New York | 10032 | — |
| Levine Children's Hospital | Charlotte | North Carolina | 28203 | — |
| Duke University | Durham | North Carolina | 27701 | — |
| Cincinnati Children'S Hospital Medical Center | Cincinnati | Ohio | 45229-3039 | — |
| The Metro Health System | Cleveland | Ohio | 44109 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | — |
| University Of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution | Pittsburgh | Pennsylvania | 15224 | — |
| Renal Disease Research Institute | Dallas | Texas | 75235 | — |
| University Of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02592798, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02592798 live on ClinicalTrials.gov.